Evidence map›Paper›PMID 42758832›Full record

ArticleScience advances2026

Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models.

Jose L Cadavid, Nikolaos Meimetis, Tyler Matsuzaki, Erin N Tevonian, Linda G Griffith, Douglas A Lauffenburger

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jose L CadavidDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9966-7352
Nikolaos MeimetisDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-2333-0187
Tyler MatsuzakiDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0009-0008-4720-3493
Erin N TevonianDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Linda G GriffithDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-1801-5548
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-0050-989X

Funding

NAMs for Clinical Translation of Therapeutics for Systemic Gynecology DiseasesUM1TR006029 · NCATS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LINDA G GRIFFITH · 2026 to 2026
$3.3M
NCATS NIH HHS UM1 TR006029
6 · The paper itself

Abstract

Preclinical models are used extensively to study diseases and therapies. In vitro monoculture or microphysiological system (MPS) platforms incorporating multiple different human cell types can emulate diseased tissues, but determining experimental conditions (e.g., media supplements) that provide the most effective translatability to humans (in vivo) is a major challenge. Using metabolic dysfunction-associated steatotic liver disease (MASLD) as a case study, we developed a machine learning framework [called LIV2TRANS (Latent In Vitro to In Vivo Translation)] that first maps MPS onto in vivo data, then elucidates translation insights, and lastly nominates experimental conditions that increase translatability. Our findings highlight TGFβ (transforming growth factor-β) as a crucial cue for MPS translatability and indicate that adding interferon-mediated JAK (Janus kinase)-STAT (signal transducer and activator of transcription) signaling perturbations could increase the predictive performance of MPS for MASLD. Last, an optimization algorithm highlights key signaling pathways to maximize germane human-relevant information captured by this MPS. This work establishes a mathematically principled approach for identifying experimental conditions that most beneficially capture in vivo-relevant molecular processes, generalizable to a wide range of diseases where suitable molecular data exist.

Indexed as

Fatty LiverModels, BiologicalSystems BiologyAlgorithmsAnimalsHumansJanus KinasesMachine LearningMicrophysiological SystemsSignal TransductionTransforming Growth Factor betaJanus KinasesTransforming Growth Factor beta

Identifiers

PMID42758832
PMCPMC13588199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.